phkineticaФармакокинетика и ФармакодинамикаPharmacokinetics and Pharmacodynamics2587-78362686-8830ООО «Издательство ОКИ»phkinetica-167Research ArticleПОИСК НОВЫХ ФАРМАКОЛОГИЧЕСКИ АКТИВНЫХ СОЕДИНЕНИЙSCREENING FOR NEW PHARMACOLOGICALLY ACTIVE COMPOUNDSСкрининг кардиотропной активности в ряду α, ω-диарилметильных производных бис-(ω-аминоалкил)аминовScreening of the compounds having cardiotropic activity among the α, ω-diarilmetil derivatives of bis-(ω-aminoalkyl)aminesКрыжановскийС. А.KryzhanovskiiS. A.SAK-538@yandex.ruЛихошерстовА. М.LikhosherstovA. M.noemail@neicon.ruЦоринИ. Б.TsorinI. B.noemail@neicon.ruСтолярукВ. Н.StolyarukV. N.noemail@neicon.ruВититноваМ. Б.VititnovaM. B.noemail@neicon.ruМокровГ. В.MokrovG. V.noemail@neicon.ruГудашеваТ. А.GudashevaT. A.noemail@neicon.ruФГБНУ «НИИ фармакологии имени В.В. Закусова»РоссияFSBI «Zakusov Institute of Pharmacology»Russian Federation201609032016021013Copyright © Крыжановский С.А., Лихошерстов А.М., Цорин И.Б., Столярук В.Н., Вититнова М.Б., Мокров Г.В., Гудашева Т.А., 20162016Крыжановский С.А., Лихошерстов А.М., Цорин И.Б., Столярук В.Н., Вититнова М.Б., Мокров Г.В., Гудашева Т.А.Kryzhanovskii S.A., Likhosherstov A.M., Tsorin I.B., Stolyaruk V.N., Vititnova M.B., Mokrov G.V., Gudasheva T.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacokinetica.ru/jour/article/view/167

Поиск новых оригинальных кардиотропных лекарственных средств, обладающих антарктической и антиишемической активностью, безусловно, является одной из наиболее актуальных задач, стоящих перед современной кардиофармакологией. В рамках решения этой проблемы впервые в ряду α, ω-диарилметильных производных бис- (ω -аминоалкил) аминов был проведён поиск соединений, обладающих подобной активностью.

screeningantiischemic and antiarrhythmic activityω-diarylmethyl derivatives of bis-(ω-aminoalkyl) aminesReferencesKantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000; 86: 5: 580-588.Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000; 86: 5: 580-588.Marzilli M. Recurrent and resistant angina: is the metabolic approach an appropriate answer? Coron. Artery Dis. 2004; 15: Suppl. 1: S23-S27.Marzilli M. Recurrent and resistant angina: is the metabolic approach an appropriate answer? Coron. Artery Dis. 2004; 15: Suppl. 1: S23-S27.Mencarelli A., Cipriani S., Renga B., D’Amore C., Palladino G., Distrutti E., Baldelli F., Fiorucci S. FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity. Nutr. Metab. Cardiovasc. Dis. 2013; 23: 2: 94-101.Mencarelli A., Cipriani S., Renga B., D’Amore C., Palladino G., Distrutti E., Baldelli F., Fiorucci S. FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity. Nutr. Metab. Cardiovasc. Dis. 2013; 23: 2: 94-101.Snorek M., Hodyc D., Sedivy V., Durisovà J., Skoumalovâ A., Wilhelm J., Neckâr J., Kolâr F., Herget J. Short-term fasting reduces the extent of myocardial infarction and incidence of reperfusion arrhythmias in rats. Physiol. Res. 2012; 61: 6: 567-574.Snorek M., Hodyc D., Sedivy V., Durisovà J., Skoumalovâ A., Wilhelm J., Neckâr J., Kolâr F., Herget J. Short-term fasting reduces the extent of myocardial infarction and incidence of reperfusion arrhythmias in rats. Physiol. Res. 2012; 61: 6: 567-574.Stanley W.C. Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies. J. Cardiovasc. Pharmacol. Ther. 2004; 9: Suppl. 1: S31-S45.Stanley W.C. Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies. J. Cardiovasc. Pharmacol. Ther. 2004; 9: Suppl. 1: S31-S45.Stanley W.C. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin. Investig. Drugs. 2002; 11: 5: 615-629.Stanley W.C. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin. Investig. Drugs. 2002; 11: 5: 615-629.Tousoulis D., Bakogiannis C., Briasoulis A., Papageorgiou N., Androulakis E., Siasos G., Latsios G., Kampoli A.M., Charakida M., Toutouzas K., Stefanadis C. Targeting myocardial metabolism for the treatment of stable angina. Curr. Pharm. Des. 2013; 19: 9: 1587-1592.Tousoulis D., Bakogiannis C., Briasoulis A., Papageorgiou N., Androulakis E., Siasos G., Latsios G., Kampoli A.M., Charakida M., Toutouzas K., Stefanadis C. Targeting myocardial metabolism for the treatment of stable angina. Curr. Pharm. Des. 2013; 19: 9: 1587-1592.Ussher J.R., Jaswal J.S., Lopaschuk G.D. Pyridine nucleotide regulation of cardiac intermediary metabolism. Circ. Res. 2012; 111: 5: 628-641.Ussher J.R., Jaswal J.S., Lopaschuk G.D. Pyridine nucleotide regulation of cardiac intermediary metabolism. Circ. Res. 2012; 111: 5: 628-641.van Bilsen M. «Energetics» of heart failure. Ann. NY Acad. Sci. 2004; 1015: 238-249.van Bilsen M. «Energetics» of heart failure. Ann. NY Acad. Sci. 2004; 1015: 238-249.Wyatt K.M., Skene C., Veitch K., Hue L., McCormack J.G. The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria. Biochem Pharmacol. 1995; 50: 10: 1599-1606.Wyatt K.M., Skene C., Veitch K., Hue L., McCormack J.G. The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria. Biochem Pharmacol. 1995; 50: 10: 1599-1606.Yamamoto S., Matsui K., Sasabe M., Ohashi N. Effect of an orally active Na+/H+ exchange inhibitor, SMP-300, on experimental angina and myocardial infarction models in rats. J. Cardiovasc. Pharmacol. 2002; 39: 2: 234-241.Yamamoto S., Matsui K., Sasabe M., Ohashi N. Effect of an orally active Na+/H+ exchange inhibitor, SMP-300, on experimental angina and myocardial infarction models in rats. J. Cardiovasc. Pharmacol. 2002; 39: 2: 234-241.Руководство по проведению доклинических исследований лекарственных средств. М.: 2013; часть 1: 385-416.2Руководство по проведению доклинических исследований лекарственных средств. М.: 2013; часть 1: 385-416.2Aldakkak M., Camara A.K., Heisner J.S., Yang M., Stowe D.F. Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts. Pharmacol Res. 2011; 64: 4: 381-392Aldakkak M., Camara A.K., Heisner J.S., Yang M., Stowe D.F. Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts. Pharmacol Res. 2011; 64: 4: 381-392

The authors declare that there are no conflicts of interest present.